...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Encap Drug Delivery and Lena Nanoceutics to Develop Nano-Capsule Technology

| Print |
Monday, 24 October 2011 09:00 (UTC + 2)

Encap_Logo

Collaboration will develop a novel bioavailability enhancing drug delivery technology

Livingston and Bradford, United Kingdom, October 24, 2011 / B3C newswire / - Encap Drug Delivery and Lena Nanoceutics today announce a collaboration agreement to develop a new drug delivery technology (Nano-Capsules) which combines Lena’s proprietary nano-particle engineering technology with Encap’s liquid filled hard capsule technology.

One of the major challenges in oral drug delivery is the development of formulations for improved absorption of poorly soluble and poorly absorbed drugs. There are a number of technologies available to enhance bioavailability, amongst others nano-crystals or nano-particles, and liquid fill formulations. The nano-particle approach results in a decrease in particle size, an increased surface area and therefore a faster dissolution. In some cases, this has been demonstrated to result in increased bioavailability of the active drug. Liquid fill formulations which can be solutions or suspensions of drug in non-aqueous liquids have also proven in many cases to produce significant bioavailability enhancement.

“We believe that there are considerable synergies to be achieved by combining the nano-particle and liquid fill technologies particularly for low solubility and low permeability compounds.” said Dr Stephen Brown, CEO at Encap. “Lena Nanoceutics have made very significant advances in the science and engineering of particle milling and we are delighted to be collaborating with them on this important project.”

Preliminary in-vitro data generated using itraconazole as a model compound has shown improved dissolution rate when both nano-particulate and liquid fill formulations were compared to standard particulate drug formulations. More interestingly, an even greater improvement was found when the nano-particle technology was combined with liquid fill technology.


About Encap Drug Delivery
Encap was established in 1989 and is a global provider of oral drug delivery and pharmaceutical development services. The company provides clients with fully integrated analytical and formulation development services, clinical trial manufacturing and high volume commercial manufacturing. Encap’s state-of-the-art facility in the UK is the world’s largest development and manufacturing facility dedicated to liquid and semi-solid filled hard capsules.

About Lena Nanoceutics
Lena Nanoceutics Ltd is a technology company which provides enhanced nanoparticle based formulations, addressing issues such as poor bioavailability, for pharmaceutical and healthcare products. This is achieved through the application of its efficient proprietary particle size reduction system together with significant expertise in formulation and drug delivery. Lena Nanoceutics’ strategy focuses on collaboration with clients to develop innovative solutions that are readily scalable to production levels.


For further information please contact:
Dr. Robbie Stewart
Encap Drug Delivery
Units 4, 5 & 6
Oakbank Park Way
Livingston
United Kingdom
EH53 0TH.
Tel: +44 (0)1506 448080
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it
 
Dr. Jason Jones
Lena Nanoceutics Limited
Institute of Pharmaceutical Innovation
Richmond Road
Bradford
BD7 1DP
Tel: +44 (0)1274 236193
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it